Abaloparatide: Physiology and What Research Reports

What abaloparatide is

Abaloparatide is a synthetic 34-amino-acid peptide modelled on human parathyroid hormone-related protein, usually written PTHrP(1-34). A 2017 review in Drugs described abaloparatide as a synthetic analogue of PTHrP(1-34) developed as a once-daily subcutaneous injection and first approved in the United States in 2017 for postmenopausal women with osteoporosis at high risk of fracture (PMID 28624872). Because it is a manufactured analogue rather than a naturally circulating molecule, abaloparatide is best understood by looking first at the endogenous hormone family it imitates.

Relationship to PTH and PTHrP

Parathyroid hormone (PTH) is an 84-amino-acid hormone secreted by the parathyroid glands and is a central regulator of calcium and phosphate handling in bone, kidney and gut. PTHrP is a structurally related protein expressed much more widely — in chondrocytes of the growth plate, mammary tissue, placenta, smooth muscle and skin — where it acts largely in a local, paracrine manner rather than as a classic circulating endocrine signal. The first 34 amino acids of both molecules contain the receptor-binding region, which is why synthetic fragments such as PTH(1-34) (teriparatide) and PTHrP(1-34)-based analogues such as abaloparatide are used experimentally and clinically. The 2017 review positioned abaloparatide within this PTHrP-analogue class (PMID 28624872).

What it does in the body

Abaloparatide and its parent peptide family signal through the type 1 parathyroid hormone receptor (PTH1R), a G-protein-coupled receptor expressed on osteoblasts, osteocytes and renal tubular cells. Activation of PTH1R engages cyclic AMP and protein kinase A signalling, which influences osteoblast recruitment, survival and activity, and indirectly influences osteoclast activity through RANKL and osteoprotegerin signalling from the osteoblast lineage. A long-standing observation in skeletal physiology is that continuous PTH1R stimulation tends to favour bone resorption, whereas brief, intermittent exposure tends to favour bone formation — the basis for calling PTH1R agonists anabolic bone agents rather than antiresorptive ones.

Because different PTH1R agonists bind the receptor with different kinetics, the class is often discussed in terms of how transient the signal is and how much it moves serum calcium. The randomised trial published in JAMA in 2016 was the source most often quoted on this point, because researchers measured hypercalcaemia in an abaloparatide arm and an open-label teriparatide arm side by side (PMID 27533157).

How abaloparatide is measured and studied

Abaloparatide itself is not routinely measured in clinical practice; instead, studies measured the skeletal and biochemical consequences of administering it. The endpoints below are the ones that appear repeatedly in the published literature.

What the literature reports

The randomised placebo-controlled trial

The largest single source on abaloparatide is the 18-month randomised clinical trial reported in JAMA in 2016, which enrolled postmenopausal women with osteoporosis and compared abaloparatide 80 µg subcutaneously daily with placebo, alongside an open-label teriparatide 20 µg daily arm (PMID 27533157). The primary endpoint was the percentage of participants with new vertebral fractures, and researchers reported a significant reduction in new vertebral fractures with abaloparatide compared with placebo, together with a reduction in nonvertebral fractures and increases in bone mineral density (PMID 27533157).

Comparative work within the anabolic class

Later work placed abaloparatide alongside the other bone-anabolic agents. A 2025 paper in the Journal of Bone and Mineral Metabolism examined the clinical effects of teriparatide, abaloparatide and romosozumab in postmenopausal osteoporosis and reported differences between the three agents in measured outcomes (PMID 39009890). Comparative analyses of this kind matter to readers of the physiology literature because they show that PTH1R agonists and sclerostin-directed agents are not interchangeable in how they shift bone formation and resorption.

Real-world observation

Trial populations are selected, so the Abaloparatide Real-World Patient Experience Study, published in JBMR Plus in 2021, surveyed people who had been prescribed abaloparatide and reported their own accounts of treatment, including how they described tolerability and what influenced whether they continued (PMID 33778325). Studies of this design capture experience outside a protocol, but they rely on self-report and lack a control group, which limits what can be inferred about cause.

Adverse Events in Abaloparatide Studies: What Studies Report

Adverse-event information in the verified literature comes mainly from the randomised trial and the real-world survey. In the 18-month randomised trial, researchers reported that hypercalcaemia occurred less often in the abaloparatide group than in the open-label teriparatide group (PMID 27533157). The 2021 real-world study reported patient-described tolerability and the considerations that affected persistence with therapy (PMID 33778325). The 2017 approval review summarised the regulatory context in which those safety data were assessed at first approval (PMID 28624872). None of these reports establish what any individual would experience.

Why the term matters to peptide readers

Abaloparatide is frequently encountered in peptide discussions for three reasons. First, it is a genuine example of a short peptide fragment developed into an approved prescription medicine, which makes it a useful case study in how receptor-binding fragments are derived from larger hormones. Second, it illustrates that the same receptor can be engaged in ways that produce different biochemical profiles, as reflected in the side-by-side calcium data from the randomised trial (PMID 27533157). Third, it shows the difference between a regulated, prescription-only peptide medicine with an approval history (PMID 28624872) and research-use-only peptides that have never been through that process.

Limits of the evidence

• The pivotal fracture data came from postmenopausal women with osteoporosis, so they do not describe other populations.
• The trial ran for 18 months, so longer-term outcomes were not addressed by that design (PMID 27533157).
• Real-world survey findings depend on self-report and lack randomised comparison (PMID 33778325).
• Comparative analyses across anabolic agents differ in design and population, which complicates direct head-to-head conclusions (PMID 39009890).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning bone health, osteoporosis medicines or laboratory monitoring. Nothing here describes a protocol, and no product is offered, referenced or endorsed.

References

• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (JAMA, 2016)
• Abaloparatide: First Global Approval (Drugs, 2017)
• Abaloparatide Real-World Patient Experience Study (JBMR Plus, 2021)
• Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis (Journal of Bone and Mineral Metabolism, 2025)